- 专利标题: RNAi-based method of screening and characterizing drug combinations
-
申请号: US13994057申请日: 2011-12-16
-
公开(公告)号: US09670486B2公开(公告)日: 2017-06-06
- 发明人: Justin Pritchard , Douglas A. Lauffenburger , Michael Hemann
- 申请人: Justin Pritchard , Douglas A. Lauffenburger , Michael Hemann
- 申请人地址: US MA Cambridge
- 专利权人: Massachusetts Institute of Technology
- 当前专利权人: Massachusetts Institute of Technology
- 当前专利权人地址: US MA Cambridge
- 代理机构: Hamilton, Brook, Smith & Reynolds, P.C.
- 国际申请: PCT/US2011/065630 WO 20111216
- 国际公布: WO2012/083243 WO 20120621
- 主分类号: C12Q1/68
- IPC分类号: C12Q1/68 ; G01N33/50 ; C12N15/10
摘要:
In one aspect, the invention is directed to a method of characterizing a mechanism of action of a combination of agents. The method comprises contacting a plurality of populations of cells with a combination of agents to be assessed, wherein each population of cells have one gene of interest targeted by a small hairpin RNA (shRNA) and wherein the gene of interest regulates cell death and a plurality of genes that regulate cell death are targeted in the plurality of populations of cells. A responsiveness of each population of cells to the combination of agents is determined, thereby obtaining an shRNA signature of the combination of agents so as to identify one or more genes that mediate a response to the combination of agents, thereby characterizing the mechanism of action of the combination of agents. In another aspect, the invention is directed to a method of determining whether a patient population treated with a first agent would benefit from a treatment using the first agent in combination with one or more additional agents. In yet another aspect, the invention is directed to method of determining whether a formulation of one or more agents maintains a mechanism of action of the one or more agents when unformulated.
公开/授权文献
信息查询